Hospital
Wayne Memorial Hospital INC
Wayne Memorial Hospital INC was paid $37.84M by Medicaid between Jan 2018 and Dec 2024, across 159 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoWAYNE MEMORIAL HOSPITAL INC
GOLDSBORO, NC 27534
GOLDSBORO, NC 27534
33aNPI1750353462assigned 02/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.84M
24GClaims724,199
24DCodes billed159
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#17 of 92
Median peer was paid$11.47M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 92,351 | $3.42M | |
| 2019 | 99,347 | $4.05M | |
| 2020 | 66,545 | $2.37M | |
| 2021 | 96,063 | $5.31M | |
| 2022 | 117,725 | $7.62M | |
| 2023 | 136,943 | $8.24M | |
| 2024incomplete | 115,225 | $6.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 41,860 | 38,513 | $8.97M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 56,822 | 52,901 | $7.93M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 23,323 | 21,319 | $5.31M |
| 41899 | Unlisted procedure, dentoalveolar structures | 8.6% | 1,901 | 1,639 | $3.26M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.4% | 32,393 | 26,859 | $1.28M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.6% | 7,133 | 6,589 | $971K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 8,972 | 8,168 | $767K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 9,369 | 8,866 | $765K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.0% | 8,094 | 7,080 | $762K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 11,572 | 10,633 | $713K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 9,317 | 5,773 | $602K |
| J3490 | Unclassified drugs | 1.5% | 92,373 | 44,723 | $576K |
147 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 4,301 | $501K |
| 80053 | Comprehensive metabolic panel | 1.2% | 58,243 | $468K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 406 | $433K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 59,870 | $432K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 13,665 | $431K |
| T1016 | Case management, each 15 minutes | 1.1% | 1,970 | $417K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 2,093 | $407K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,693 | $376K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,547 | $263K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,367 | $233K |
| 81001 | <1% | 46,819 | $154K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 68,304 | $151K |
| 84484 | <1% | 19,164 | $140K | |
| 97597 | <1% | 2,852 | $121K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,940 | $83K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,472 | $75K |
| 87150 | <1% | 2,070 | $66K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,281 | $62K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 769 | $60K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,507 | $60K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,245 | $60K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,567 | $55K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,675 | $54K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,675 | $54K |
| 83690 | <1% | 6,295 | $47K | |
| 81025 | <1% | 5,564 | $45K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 396 | $43K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,743 | $43K |
| 84703 | <1% | 4,534 | $42K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 215 | $27K |
| 29580 | <1% | 418 | $26K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 148 | $23K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 23 | $20K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,160 | $19K |
| 82553 | <1% | 3,487 | $19K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,389 | $18K |
| 80306 | <1% | 698 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,637 | $17K |
| Q3014 | Telehealth originating site facility fee | <1% | 569 | $17K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 270 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,896 | $14K |
| 81513 | <1% | 1,207 | $14K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 89 | $13K |
| 82550 | <1% | 3,729 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,438 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,137 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 264 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 123 | $10K |
| 83605 | <1% | 1,347 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 36 | $10K |
| 80061 | Lipid panel | <1% | 540 | $9K |
| 85027 | <1% | 1,445 | $9K | |
| 29581 | <1% | 160 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,015 | $8K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $8K |
| 84439 | <1% | 703 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 662 | $8K |
| 82962 | <1% | 4,152 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,078 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,987 | $7K |
| 85610 | <1% | 2,405 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,813 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $6K |
| 0012A | <1% | 101 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 306 | $5K |
| 87081 | <1% | 603 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 959 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 143 | $5K |
| 0011A | <1% | 107 | $4K | |
| 94664 | <1% | 553 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 371 | $4K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 136 | $4K |
| 80051 | <1% | 456 | $4K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 69 | $3K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 25 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 123 | $3K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 237 | $3K |
| 86850 | <1% | 183 | $3K | |
| 84702 | <1% | 222 | $3K | |
| 86780 | <1% | 132 | $3K | |
| 93320 | <1% | 25 | $2K | |
| 87040 | <1% | 189 | $2K | |
| 87088 | <1% | 336 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 46 | $2K |
| 83735 | <1% | 392 | $2K | |
| 84460 | <1% | 459 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 862 | $2K |
| 83880 | <1% | 115 | $2K | |
| 87186 | <1% | 242 | $2K | |
| 86803 | <1% | 109 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 35 | $2K |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 69 | $2K |
| 83615 | <1% | 222 | $2K | |
| 82570 | <1% | 222 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 840 | $1K |
| V2632 | Posterior chamber intraocular lens | <1% | 75 | $1K |
| 93325 | <1% | 25 | $1K | |
| 84550 | <1% | 224 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 191 | $1K |
| 86762 | <1% | 67 | $1K | |
| 84156 | <1% | 221 | $1K | |
| 86787 | <1% | 69 | $1K | |
| 85730 | <1% | 171 | $941.14 | |
| 86677 | <1% | 144 | $914.72 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 164 | $882.01 |
| 86901 | <1% | 241 | $849.58 | |
| 87340 | <1% | 75 | $808.38 | |
| 86900 | <1% | 227 | $805.05 | |
| A9270 | Non-covered item or service | <1% | 13,588 | $795.70 |
| 82565 | <1% | 274 | $778.37 | |
| 74022 | <1% | 12 | $678.98 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 125 | $569.54 |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | <1% | 13 | $519.63 |
| 86592 | <1% | 106 | $472.59 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 62 | $446.40 |
| 87077 | <1% | 62 | $414.65 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 18 | $400.23 |
| 87210 | <1% | 94 | $390.04 | |
| 87420 | <1% | 27 | $385.56 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 511 | $364.19 |
| 97605 | <1% | 19 | $357.10 | |
| 83021 | <1% | 13 | $329.40 | |
| J2540 | Injection, penicillin g potassium, up to 600,000 units | <1% | 62 | $322.57 |
| 86696 | <1% | 15 | $319.98 | |
| 86701 | <1% | 33 | $309.68 | |
| 85660 | <1% | 55 | $309.60 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 146 | $297.75 |
| 86695 | <1% | 15 | $217.88 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 49 | $212.80 |
| 87350 | <1% | 16 | $203.29 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 32 | $184.01 |
| C9447 | Injection, phenylephrine and ketorolac, 4 ml vial | <1% | 31 | $171.09 |
| 86141 | <1% | 12 | $137.19 | |
| 82950 | <1% | 25 | $124.32 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 43 | $122.89 |
| 87070 | <1% | 30 | $117.26 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 67 | $85.31 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 29 | $81.37 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 25 | $77.47 |
| 84520 | <1% | 235 | $62.37 | |
| 86140 | <1% | 16 | $47.39 | |
| 82948 | <1% | 20 | $46.53 | |
| 87205 | <1% | 28 | $44.94 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 659 | $5.66 |
| 80143 | 0% | 14 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 197 | $0.00 |
| 91301 | 0% | 215 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMA, WILLIAM (SR VICE PRESIDENT, FINANCE / CFO)
| Provider | Location | Paid |
|---|---|---|
| Wayne Memorial Hospital | Goldsboro, NC | $41K |
| Wayne Memorial Hospital | Goldsboro, NC | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.